A Scientist from TNMU Participated in the Scientific Meeting of the European Society of Cardiology

From November 7 to 9, 2024, Associate Professor of the Department of Emergency and Urgent Medical Care, Sofiia Lypovetska, took part in the European Society of Cardiology scientific meeting “Advances in Cardiovascular Pharmacotherapy” (EuroCVP – 2024) in Budapest. The conference was held at the Semmelweis University’s Basic Medical Science Center.

The event gathered renowned global experts in the field of cardiovascular pharmacotherapy. It provided a unique platform for a multidisciplinary community of cardiologists, pharmacologists, and radiologists to review current guidelines, discuss new treatment methods, and analyze the latest clinical research results in cardiovascular pharmacotherapy.

The conference program included sessions on the following topics:

New molecules in cardiovascular therapy for dyslipidemia, arterial hypertension, atrial fibrillation, heart failure, and more

Safety of cardiovascular pharmacotherapy

Innovations in medical technologies

Cardio-oncology

RNA therapy

Customizing antithrombotic therapy to the patient’s “size” and needs

Discussion of new ESC recommendations

Personalized pharmacotherapy

Pharmacogenomics and other risk stratification strategies

Utilizing CYP2C19 testing in cardiovascular medicine to optimize the benefit/risk ratio of medications

New molecules in cardiovascular therapy for dyslipidemia, arterial hypertension, atrial fibrillation, heart failure, and more

Timely diagnosis is the cornerstone of successful patient treatment. Significant advancements in imaging technologies were highlighted during the conference. A new photon-counting computed tomography model, the NAEOTOM Alpha, was presented. Its software enables heart imaging with a resolution of less than 0.2 mm, providing undeniable advantages in evaluating arterial patency at the endothelial level and structural changes in the myocardium.

During the congress, Sofiia Lypovetska presented a poster entitled “Impact of Secondary Prevention Medical Therapy in Patients with Myocardial Infarction with Non-Obstructive Coronary Arteries.”